Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines

Pierre Van Damme; Paolo Bonanni; F Xavier Bosch; Elmar A Joura; Susanne Krüger Kjaer; Chris J L M Meijer; Karl-Ulrich Petry; Benoit Soubeyrand; Thomas Verstraeten; Margaret Stanley

doi:10.1016/j.vaccine.2015.12.063

Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines

Pierre Van Damme, Paolo Bonanni, F Xavier Bosch, Elmar A Joura, Susanne Krüger Kjaer, Chris J L M Meijer, Karl-Ulrich Petry, Benoit Soubeyrand, Thomas Verstraeten, Margaret Stanley

Department of Clinical Medicine

29 Citations (Scopus)

Abstract

With the availability of the nonavalent human papillomavirus (HPV) vaccine, vaccinees, parents and healthcare providers need guidance on how to complete an immunization course started with the bi- or quadrivalent vaccine and whether to revaccinate individuals who have completed a full immunization course with the bi- or quadrivalent vaccine. To answer these questions three parameters should be considered: age at the start of vaccination (9 to 14 years of age versus 15 years and older, the cut-off for 2 or 3 doses schedule), the number of doses already received and the time interval between doses. Based on a number of scenarios, we propose that the 9-valent vaccine can be used to complete an incomplete vaccination regimen or might be added to a previous completed schedule to extend protection.

Original language	English
Journal	Vaccine
Volume	34
Issue number	6
Pages (from-to)	757-761
ISSN	0264-410X
DOIs	https://doi.org/10.1016/j.vaccine.2015.12.063 https://doi.org/10.1016/j.vaccine.2016.07.035
Publication status	Published - 3 Feb 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

Cite this

Van Damme, P., Bonanni, P., Bosch, F. X., Joura, E. A., Krüger Kjaer, S., Meijer, C. J. L. M., Petry, K.-U., Soubeyrand, B., Verstraeten, T., & Stanley, M. (2016). Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines. Vaccine, 34(6), 757-761. https://doi.org/10.1016/j.vaccine.2015.12.063, https://doi.org/10.1016/j.vaccine.2016.07.035

Van Damme, P, Bonanni, P, Bosch, FX, Joura, EA, Krüger Kjaer, S, Meijer, CJLM, Petry, K-U, Soubeyrand, B, Verstraeten, T & Stanley, M 2016, 'Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines', Vaccine, vol. 34, no. 6, pp. 757-761. https://doi.org/10.1016/j.vaccine.2015.12.063, https://doi.org/10.1016/j.vaccine.2016.07.035

@article{bb34c6010b1944f39124007067c8b933,

title = "Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines",

abstract = "With the availability of the nonavalent human papillomavirus (HPV) vaccine, vaccinees, parents and healthcare providers need guidance on how to complete an immunization course started with the bi- or quadrivalent vaccine and whether to revaccinate individuals who have completed a full immunization course with the bi- or quadrivalent vaccine. To answer these questions three parameters should be considered: age at the start of vaccination (9 to 14 years of age versus 15 years and older, the cut-off for 2 or 3 doses schedule), the number of doses already received and the time interval between doses. Based on a number of scenarios, we propose that the 9-valent vaccine can be used to complete an incomplete vaccination regimen or might be added to a previous completed schedule to extend protection.",

author = "{Van Damme}, Pierre and Paolo Bonanni and Bosch, {F Xavier} and Joura, {Elmar A} and {Kr{\"u}ger Kjaer}, Susanne and Meijer, {Chris J L M} and Karl-Ulrich Petry and Benoit Soubeyrand and Thomas Verstraeten and Margaret Stanley",

year = "2016",

month = feb,

day = "3",

doi = "10.1016/j.vaccine.2015.12.063",

language = "English",

volume = "34",

pages = "757--761",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines

AU - Van Damme, Pierre

AU - Bonanni, Paolo

AU - Bosch, F Xavier

AU - Joura, Elmar A

AU - Krüger Kjaer, Susanne

AU - Meijer, Chris J L M

AU - Petry, Karl-Ulrich

AU - Soubeyrand, Benoit

AU - Verstraeten, Thomas

AU - Stanley, Margaret

PY - 2016/2/3

Y1 - 2016/2/3

N2 - With the availability of the nonavalent human papillomavirus (HPV) vaccine, vaccinees, parents and healthcare providers need guidance on how to complete an immunization course started with the bi- or quadrivalent vaccine and whether to revaccinate individuals who have completed a full immunization course with the bi- or quadrivalent vaccine. To answer these questions three parameters should be considered: age at the start of vaccination (9 to 14 years of age versus 15 years and older, the cut-off for 2 or 3 doses schedule), the number of doses already received and the time interval between doses. Based on a number of scenarios, we propose that the 9-valent vaccine can be used to complete an incomplete vaccination regimen or might be added to a previous completed schedule to extend protection.

AB - With the availability of the nonavalent human papillomavirus (HPV) vaccine, vaccinees, parents and healthcare providers need guidance on how to complete an immunization course started with the bi- or quadrivalent vaccine and whether to revaccinate individuals who have completed a full immunization course with the bi- or quadrivalent vaccine. To answer these questions three parameters should be considered: age at the start of vaccination (9 to 14 years of age versus 15 years and older, the cut-off for 2 or 3 doses schedule), the number of doses already received and the time interval between doses. Based on a number of scenarios, we propose that the 9-valent vaccine can be used to complete an incomplete vaccination regimen or might be added to a previous completed schedule to extend protection.

U2 - 10.1016/j.vaccine.2015.12.063

DO - 10.1016/j.vaccine.2015.12.063

M3 - Journal article

SN - 0264-410X

VL - 34

SP - 757

EP - 761

JO - Vaccine

JF - Vaccine

IS - 6

ER -

Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this